IMBP'S IPLATFORM™
A NEW ERA IN BIOPHARMACEUTICAL EXCELLENCE
At iMetabolic Biopharma Corporation Biotechnology Company, we are dedicated to revolutionizing the biotechnology industry. With a focus on innovation and scientific excellence, we are working to find new solutions to some of the world's most pressing problems. Our team of experts brings together diverse backgrounds and skill sets, enabling us to tackle complex challenges and develop new products that have the potential to change lives. We are committed to making a positive impact on society, and we believe that biotechnology can be a powerful tool for addressing global challenges such as disease, food security, and environmental sustainability.
Learn More
To learn more about our groundbreaking work and the products we are developing, visit our media page.
OUR AREA OF FOCUS
The Obesity Epidemic
Obesity and its related issues have reached global proportions. In the United States alone, 40% of the population faces obesity, with a total of 73% either obese or overweight. This crisis is not just about numbers; it's a matter of life and death. Cardiovascular disease alone, driven by obesity, accounts for one in four deaths and costs the nation $214 billion annually. The fight against obesity is urgent and real.
To address this critical issue, we're leading the charge with cutting-edge solutions, turning the tide on obesity’s comorbidities and setting new standards for patient treatment.
DRUG CANDIDATES
CARDIOVASCULAR DISEASES
iMBP-XR-02/03: Specifically targets small, dense low-density lipoprotein for enhanced hepatic clearance to address atherosclerotic CVD.
iMBP-AE-201: For the clearance of dysfunctional low-density lipoprotein particles resulting from the ApoE2/E2 genotype in the treatment of the orphan indication Hyperlipoproteinemia Type III.
metabolic Diseases
iMBP-001/150: Metabolic inhibitor antagonists for preserving lipase activity in addressing Familial Chylomicronemia Syndrome (FCS)/Acute pancreatitis.
Neurodegenerative Diseases
iMBP-AD-500: Attacks an innovative target to simultaneously address lipid metabolism, inflammation and CNS plaquing in the treatment of Mild Cognitive Impairment (MCI) and Alzheimer’s Disease.